CY1116488T1 - Αντισωματα anti-προπερδινης - Google Patents

Αντισωματα anti-προπερδινης

Info

Publication number
CY1116488T1
CY1116488T1 CY20151100366T CY151100366T CY1116488T1 CY 1116488 T1 CY1116488 T1 CY 1116488T1 CY 20151100366 T CY20151100366 T CY 20151100366T CY 151100366 T CY151100366 T CY 151100366T CY 1116488 T1 CY1116488 T1 CY 1116488T1
Authority
CY
Cyprus
Prior art keywords
perpetin
antibodies
inhibiting
alternative pathway
complement
Prior art date
Application number
CY20151100366T
Other languages
English (en)
Inventor
Rekha Bansal
Original Assignee
Novelmed Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelmed Therapeutics, Inc. filed Critical Novelmed Therapeutics, Inc.
Publication of CY1116488T1 publication Critical patent/CY1116488T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Μέθοδος αναστολής εναλλακτικής οδού ενεργοποίησης του συμπληρώματος σε ένα θηλαστικό που περιλαμβάνει χορήγηση μιας ποσότητας ενός αντισώματος και/ή κλάσματος αυτού, το οποίο προσδένεται ειδικώς σε έναν επίτοπο του Ν άκρου προπερδίνης, αποτελεσματικής στην αναστολή εναλλακτικής οδού του συμπληρώματος στο υποκείμενο.
CY20151100366T 2008-03-03 2015-04-21 Αντισωματα anti-προπερδινης CY1116488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3312708P 2008-03-03 2008-03-03
EP08772137.9A EP2262831B1 (en) 2008-03-03 2008-06-27 Anti-properdin antibodies

Publications (1)

Publication Number Publication Date
CY1116488T1 true CY1116488T1 (el) 2017-03-15

Family

ID=41056304

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100366T CY1116488T1 (el) 2008-03-03 2015-04-21 Αντισωματα anti-προπερδινης

Country Status (11)

Country Link
US (1) US8435512B2 (el)
EP (1) EP2262831B1 (el)
AU (1) AU2008351988B2 (el)
CY (1) CY1116488T1 (el)
DK (1) DK2262831T3 (el)
ES (1) ES2538114T3 (el)
HR (1) HRP20150434T1 (el)
PL (1) PL2262831T3 (el)
PT (1) PT2262831E (el)
SI (1) SI2262831T1 (el)
WO (1) WO2009110918A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2044111T3 (en) 2006-06-21 2014-11-17 Musc Found For Res Dev OBJECTIVE TO COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES
US9066925B2 (en) 2009-07-02 2015-06-30 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
CA2811221C (en) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
EP3524258A1 (en) 2011-06-22 2019-08-14 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6293659B2 (ja) * 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
PE20150159A1 (es) * 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
US10711056B2 (en) * 2011-12-28 2020-07-14 Novelmed Therapeutics, Inc. Aglycosylated anti-properdin antibodies
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
ES2650917T3 (es) 2013-08-07 2018-01-23 Alexion Pharmaceuticals, Inc. Proteínas biomarcadoras del síndrome urémico hemolítico atípico (SUHA)
BR112016019825A2 (pt) * 2014-02-27 2017-10-17 Allergan Inc anticorpos do fator bb do complemento
US20180074077A1 (en) * 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
EP3666901A1 (en) * 2015-10-30 2020-06-17 F. Hoffmann-La Roche AG Methods of measuring factor d activity and potency of factor d inhibitors
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
US20230054202A1 (en) * 2020-01-08 2023-02-23 Zydus Lifesciences Limited Anti-properdin antibodies and preparation thereof
EP4193151A1 (en) * 2020-08-04 2023-06-14 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010009A1 (en) * 1997-08-26 1999-03-04 Gliatech Inc. A process for inhibiting complement activation via the alternative pathway
AU2003212475A1 (en) * 2002-03-01 2003-09-16 Incyte Corporation Immune response associated proteins
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用

Also Published As

Publication number Publication date
ES2538114T3 (es) 2015-06-17
SI2262831T1 (sl) 2015-10-30
PL2262831T4 (pl) 2015-08-31
WO2009110918A1 (en) 2009-09-11
AU2008351988A1 (en) 2009-09-11
US20110008340A1 (en) 2011-01-13
HRP20150434T1 (hr) 2015-06-05
PT2262831E (pt) 2015-05-18
PL2262831T3 (pl) 2015-08-31
EP2262831B1 (en) 2015-01-21
AU2008351988B2 (en) 2013-07-25
US8435512B2 (en) 2013-05-07
DK2262831T3 (en) 2015-04-27
EP2262831A1 (en) 2010-12-22
EP2262831A4 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CY1118906T1 (el) Χαμηλης συγγενειας αντισωματα υποδοχεα αιματοεγκεφαλικου φραγμου και χρησεις αυτων
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CR20140585A (es) Proteinas de union a antigeno st2
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CR10068A (es) Anticuerpos anti mn y métodos para su utilización
CY1115932T1 (el) Σκευασμα αντισωματος
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano